959983-21-2

Basic information

• Product Name: cycloprop[d]indolo[2,1-a][2]benzazepine-1a(2H)-carboxylic acid, 8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxy-, methyl ester, (+/-)-
• Synonyms: cycloprop[d]indolo[2,1-a][2]benzazepine-1a(2H)-carboxylic acid, 8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxy-, methyl ester, (+/-)-
• CAS NO: 959983-21-2
• Molecular Weight: 565.69
• Mol File: 959983-21-2.mol

Chemical Properties

• CAS DataBase Reference: cycloprop[d]indolo[2,1-a][2]benzazepine-1a(2H)-carboxylic acid, 8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxy-, methyl ester, (+/-)-(CAS DataBase Reference)
• NIST Chemistry Reference: cycloprop[d]indolo[2,1-a][2]benzazepine-1a(2H)-carboxylic acid, 8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxy-, methyl ester, (+/-)-(959983-21-2)
• EPA Substance Registry System: cycloprop[d]indolo[2,1-a][2]benzazepine-1a(2H)-carboxylic acid, 8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxy-, methyl ester, (+/-)-(959983-21-2)

Safety Data

• Hazardous Substances Data: 959983-21-2(Hazardous Substances Data)

Upstream product

• 928844-30-8 13-cyclohexyl-3-methoxy-7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylic acid 10-(1,1-dimethylethyl) ester 6-methyl ester 
• 902148-54-3 13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-6-carboxylic acid methyl ester 
• 2181-42-2 trimethylsulphonium iodide 
• 1774-47-6 trimethylsulfoxonium iodide 
• 879498-90-5 1H-indole-6-carboxylic acid, 2-bromo-3-cyclohexyl-, 1,1-dimethylethyl ester 
• 108-94-1 cyclohexanone 
• 902148-40-7 2-bromo-3-cyclohexyl-N-[(dimethylamino)sulfonyl]-1H-indole-6-carboxamide 
• 958002-14-7 6H-Isoindolo[2,1-a]indole-3-carboxamide, 11-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-ethoxy-8-methoxy- 
• 928844-26-2 3-cyclohexyl-N-[(dimethylamino)sulfonyl]-2-(2-formyl-4-methoxyphenyl)-1H-indole-6-carboxamide 
• 902148-53-2 11-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-hydroxy-8-methoxy-6H-isoindolo[2,1-a]indole-3-carboxamide 
• 50820-65-0 indole-6-carboxylic acid methyl ester 
• 1670-82-2 Indole-6-carboxylic acid 
• 494799-76-7 2-bromo-3-cyclohexyl-1H-indole-6-carboxylic acid 
• 494799-19-8 methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate 

Downstream Products

• 1058073-32-7 (+/-)-8-cyclohexyl-N-(dimethylaminosulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-(hydroxymethyl)-cycloprop[d]indolo[2,1-a][2]benzazepine-5-carboxamide 
• 959983-11-0 1,1-dimethylethyl (8-cyclohexyl-5-((((dimethylamino)sulfonyl)amino)carbonyl)-11-(methyloxy)-1,12b-dihydrocyclopropa[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl)carbamate 
• 959983-12-1 1a-amino-8-cyclohexyl-N-((dimethylamino)sulfonyl)-11-(methyloxy)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide hydrochloride 
• 959983-23-4 8-cyclohexyl-5-(((dimethylamino)sulfonyl)carbamoyl)-11-methoxy-1,12b-dihydrocyclopropa[d]indolo[2,1-a][2]benzazepine-1a(2H)-carbonyl azide 
• 1045705-30-3 8-cyclohexyl-N-(dimethylsulfamoyl)-11-methoxy-1a-((4-morpholinylsulfonyl)amino)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide 
• 1045705-05-2 8-cyclohexyl-N-((dimethylamino)sulfonyl)-11-(methyloxy)-1a-((4-morpholinyl(oxo)acetyl)amino)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide 
• 928843-71-4 (1aR,12bS)-8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepine-1a(2H)-carboxylic acid 
• 1058073-37-2 (+/-)-8-cyclohexyl-N-(dimethylaminosulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-(chloromethyl)-cycloprop[d]indolo[2,1-a][2]benzazepine-5-carboxamide 
• 1058073-47-4 (+/-)-8-cyclohexyl-N-(dimethylaminosulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-(morpholinomethyl)-cycloprop[d]indolo[2,1-a][2]benzazepine-5-carboxamide 
• 1058073-42-9 (+/-)-8-cyclohexyl-N-(dimethylaminosulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-[(morpholine-4-carbonyloxy)methyl]-cycloprop[d]indolo[2,1-a][2]benzazepine-5-carboxamide 

Relevant articles and documents

The First Kilogram Synthesis of Beclabuvir, an HCV NS5B Polymerase Inhibitor

The process development and kilogram-scale synthesis of beclabuvir (BMS-791325, 1) is described. The convergent synthesis features the use of asymmetric catalysis to generate a chiral cyclopropane fragment and coupling with an indole fragment via an alkyl

Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS

The invention encompasses compounds of formula (I) as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.